Antares Pharma, Inc.'s partner Teva Pharmaceutical Industries Ltd. has launched its new Tjet needle-free injector system for the administration of human growth hormone (hGH). The injector system of Antares Pharma is intended for the administration of human growth hormone (hGH). Teva hGH product Tev-Tropin [somatropin (rDNA) for injection] will come in combination with Tjet.
Robert F. Apple EVP, CFO and President of the Parenteral Products Division stated: “We are pleased that this product is now commercially available in the United States for children with growth hormone deficiency in a convenient, more user-friendly format and marks the first product launched under our strategic collaboration with Teva. We look forward to growing our business through additional product sales and royalty revenue with the launch of the Tjet device.”